A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)

ATHENA (ClinicalTrials.gov identifier: NCT03522246) was designed to evaluate rucaparib first-line maintenance treatment in a broad patient population, including those without BRCA1 or BRCA2 (BRCA) mutations or other evidence of homologous recombination deficiency (HRD), or high-risk clinical charact...

Descripción completa

Detalles Bibliográficos
Autores principales: Monk, Bradley J., Parkinson, Christine, Lim, Myong Cheol, O'Malley, David M., Oaknin, Ana, Wilson, Michelle K., Coleman, Robert L., Lorusso, Domenica, Bessette, Paul, Ghamande, Sharad, Christopoulou, Athina, Provencher, Diane, Prendergast, Emily, Demirkiran, Fuat, Mikheeva, Olga, Yeku, Oladapo, Chudecka-Glaz, Anita, Schenker, Michael, Littell, Ramey D., Safra, Tamar, Chou, Hung-Hsueh, Morgan, Mark A., Drochýtek, Vít, Barlin, Joyce N., Van Gorp, Toon, Ueland, Fred, Lindahl, Gabriel, Anderson, Charles, Collins, Dearbhaile C., Moore, Kathleen, Marme, Frederik, Westin, Shannon N., McNeish, Iain A., Shih, Danny, Lin, Kevin K., Goble, Sandra, Hume, Stephanie, Fujiwara, Keiichi, Kristeleit, Rebecca S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746782/
https://www.ncbi.nlm.nih.gov/pubmed/35658487
http://dx.doi.org/10.1200/JCO.22.01003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746782/
https://www.ncbi.nlm.nih.gov/pubmed/35658487
http://dx.doi.org/10.1200/JCO.22.01003

Ejemplares similares